As of 2010, there have been no MCS
treatment results studied in an objective clinical
setting. Previous investigators have found by
using microcurrent stimulation improved vision,
especially those patients in the early dry stage.
All traditionally trained ophthalmologists were
taught there is no therapy, for patients in the
early dry stage. Because of the consistency of
positive results with investigators in the past, it
is imperative that this form of therapy be
critically evaluated in a proper clinical study that
has a control population. It should have detailed
documentation on patients selected, and those who
were given placebo treatment. There needs to be an
objective way of evaluating the success of
microcurrent stimulation to support what has been
shown in the past.
Electric stimulation through microcurrent therapy is thought to increase blood flow and thereby increase retinal function. If retinal physiology is improved by using microcurrent stimulation therapy, then a before and after treatment using a modified electroretinogram as a diagnostic test should show an improvement. At present, an improvement in visual acuity is how success is now measured.
An electroretinogram (ERG) is a record of retinal action currents registered by a galvanometer similar to an electrocardiogram (EKG). The electroretinogram test may confirm what has been shown by previous observations. Such a study is now being considered. More details will be forthcoming. Meanwhile, patients with dry macular degeneration may still benefit visually from microcurrent therapy now. It is important that these patients treated with MCS be followed by an eye doctor for their visual progress so that the proper number of 6 minute cycles be performed daily.